JOP20190246A1 - جسم مضاد أحادي النسيلة لـ pd-l1 - Google Patents
جسم مضاد أحادي النسيلة لـ pd-l1Info
- Publication number
- JOP20190246A1 JOP20190246A1 JOP/2019/0246A JOP20190246A JOP20190246A1 JO P20190246 A1 JOP20190246 A1 JO P20190246A1 JO P20190246 A JOP20190246 A JO P20190246A JO P20190246 A1 JOP20190246 A1 JO P20190246A1
- Authority
- JO
- Jordan
- Prior art keywords
- monoclonal antibody
- antibodies
- methods
- relates
- biotechnology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
الملخص جسم مضاد أحادي النسيلة لـ PD-L1 يتعلق الاختراع الحالي بمجال التكنولوجيا الحيوية ويوفر أجسام مضادة والتي ترتبط على وجه التحديد بـ PD-L1. يتعلق الاختراع أيضاً بـ DNA يقوم بترميز الأجسام المضادة المذكورة، بنواقل تعبير وراثي مقابلة وبطرق لإنتاج الأجسام المضادة المذكورة وطرق للعلاج باستخدامها.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017113141A RU2665790C1 (ru) | 2017-04-17 | 2017-04-17 | Моноклональное антитело к pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190246A1 true JOP20190246A1 (ar) | 2019-10-16 |
Family
ID=63459922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0246A JOP20190246A1 (ar) | 2017-04-17 | 2017-06-16 | جسم مضاد أحادي النسيلة لـ pd-l1 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11236167B2 (ar) |
EP (1) | EP3613770A4 (ar) |
JP (2) | JP2020516323A (ar) |
KR (1) | KR20190140979A (ar) |
CN (1) | CN111247166B (ar) |
AR (1) | AR113223A1 (ar) |
AU (1) | AU2018255132A1 (ar) |
BR (1) | BR112019021781A2 (ar) |
CA (1) | CA3060395A1 (ar) |
CL (1) | CL2019002894A1 (ar) |
CO (1) | CO2019011458A2 (ar) |
EA (1) | EA201992206A1 (ar) |
JO (1) | JOP20190246A1 (ar) |
MA (1) | MA47221A1 (ar) |
NZ (1) | NZ758093A (ar) |
PE (1) | PE20191786A1 (ar) |
PH (1) | PH12019502298A1 (ar) |
RU (1) | RU2665790C1 (ar) |
UY (1) | UY37683A (ar) |
WO (1) | WO2018194496A2 (ar) |
ZA (1) | ZA201907065B (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170135860A (ko) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
WO2022121846A1 (zh) * | 2020-12-08 | 2022-06-16 | 博际生物医药科技(杭州)有限公司 | Pd-l1抗体及其应用 |
EP4359445A1 (en) * | 2021-06-21 | 2024-05-01 | Joint Stock Company "Biocad" | Isolated bispecific antibody that specifically binds to cd47 and pd-l1 |
WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
CA2086417C (en) | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
US5565323A (en) | 1994-03-30 | 1996-10-15 | Mitokor | Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease |
US5537905A (en) | 1994-09-08 | 1996-07-23 | Zimmer Industries, Inc. | Nicked cutting rule |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
EP3530672B1 (en) | 2008-09-26 | 2024-05-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
NZ628923A (en) * | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US20110280877A1 (en) * | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
SG11201402603WA (en) * | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CA3175758A1 (en) * | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
CA3139031A1 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
NZ728749A (en) * | 2014-08-05 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
US9988452B2 (en) * | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
KR20170135860A (ko) * | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
-
2017
- 2017-04-17 RU RU2017113141A patent/RU2665790C1/ru active
- 2017-06-16 JO JOP/2019/0246A patent/JOP20190246A1/ar unknown
-
2018
- 2018-04-11 NZ NZ758093A patent/NZ758093A/en unknown
- 2018-04-11 EA EA201992206A patent/EA201992206A1/ru unknown
- 2018-04-11 MA MA47221A patent/MA47221A1/fr unknown
- 2018-04-11 CN CN201880040390.1A patent/CN111247166B/zh active Active
- 2018-04-11 KR KR1020197033829A patent/KR20190140979A/ko active IP Right Grant
- 2018-04-11 BR BR112019021781A patent/BR112019021781A2/pt unknown
- 2018-04-11 PE PE2019002020A patent/PE20191786A1/es unknown
- 2018-04-11 AU AU2018255132A patent/AU2018255132A1/en active Pending
- 2018-04-11 WO PCT/RU2018/050039 patent/WO2018194496A2/ru unknown
- 2018-04-11 JP JP2020506702A patent/JP2020516323A/ja active Pending
- 2018-04-11 US US16/605,865 patent/US11236167B2/en active Active
- 2018-04-11 EP EP18786945.8A patent/EP3613770A4/en active Pending
- 2018-04-11 CA CA3060395A patent/CA3060395A1/en active Pending
- 2018-04-16 AR ARP180100958A patent/AR113223A1/es unknown
- 2018-04-17 UY UY0001037683A patent/UY37683A/es unknown
-
2019
- 2019-10-07 PH PH12019502298A patent/PH12019502298A1/en unknown
- 2019-10-10 CL CL2019002894A patent/CL2019002894A1/es unknown
- 2019-10-16 CO CONC2019/0011458A patent/CO2019011458A2/es unknown
- 2019-10-25 ZA ZA2019/07065A patent/ZA201907065B/en unknown
-
2023
- 2023-03-02 JP JP2023031932A patent/JP2023081942A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2019002894A1 (es) | 2020-03-13 |
CA3060395A1 (en) | 2019-11-18 |
EP3613770A4 (en) | 2021-01-27 |
RU2665790C1 (ru) | 2018-09-04 |
BR112019021781A2 (pt) | 2020-05-05 |
US20200369771A1 (en) | 2020-11-26 |
EP3613770A2 (en) | 2020-02-26 |
US11236167B2 (en) | 2022-02-01 |
CN111247166B (zh) | 2024-03-26 |
CO2019011458A2 (es) | 2020-01-17 |
EA201992206A1 (ru) | 2020-02-21 |
CN111247166A (zh) | 2020-06-05 |
UY37683A (es) | 2018-11-30 |
JP2023081942A (ja) | 2023-06-13 |
MA47221A1 (fr) | 2020-04-30 |
WO2018194496A3 (ru) | 2019-01-10 |
WO2018194496A2 (ru) | 2018-10-25 |
NZ758093A (en) | 2022-09-30 |
AR113223A1 (es) | 2020-02-19 |
PH12019502298A1 (en) | 2020-07-06 |
AU2018255132A2 (en) | 2019-11-07 |
JP2020516323A (ja) | 2020-06-11 |
KR20190140979A (ko) | 2019-12-20 |
AU2018255132A1 (en) | 2019-10-31 |
ZA201907065B (en) | 2020-09-30 |
PE20191786A1 (es) | 2019-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502283A1 (en) | Anti-lag3 antibodies | |
PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
MX2019002946A (es) | Anticuerpos anti-pd-1 y sus usos. | |
MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
CL2016001028A1 (es) | Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh. | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
PH12021550991A1 (en) | Monoclonal antibody that specifically binds to cd20 | |
PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
CR20210332A (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
EA201992747A1 (ru) | Антитела к fam19a5 и их применение |